21.14MMarket Cap-578P/E (TTM)
0.3700High0.3573Low122.85KVolume0.3573Open0.3590Pre Close45.09KTurnover0.23%Turnover RatioLossP/E (Static)57.14MShares0.748752wk High5.14P/B19.46MFloat Cap0.305452wk Low--Dividend TTM52.58MShs Float836.0000Historical High--Div YieldTTM3.54%Amplitude0.2910Historical Low0.3670Avg Price1Lot Size
AIM ImmunoTech Stock Forum
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
No comment yet